Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy.
Di Pastena F, Pond G, Tsakiridis EE, Gouveia A, Ahmadi E, Biziotis OD, Ali A, Swaminath A, Okawara G, Ellis PM, Abdulkarim B, Ahmed N, Robinson A, Roa W, Valdes M, Kavsak P, Wierzbicki M, Wright J, Steinberg G, Tsakiridis T. Di Pastena F, et al. Among authors: ellis pm. Radiat Oncol. 2024 Nov 7;19(1):155. doi: 10.1186/s13014-024-02546-y. Radiat Oncol. 2024. PMID: 39511611 Free PMC article. Clinical Trial.
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.
Arnold AM, Seymour L, Smylie M, Ding K, Ung Y, Findlay B, Lee CW, Djurfeldt M, Whitehead M, Ellis P, Goss G, Chan A, Meharchand J, Alam Y, Gregg R, Butts C, Langmuir P, Shepherd F; National Cancer Institute of Canada Clinical Trials Group Study BR.20. Arnold AM, et al. J Clin Oncol. 2007 Sep 20;25(27):4278-84. doi: 10.1200/JCO.2007.12.3083. J Clin Oncol. 2007. PMID: 17878480 Clinical Trial.
Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.
Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, Kreisman H, Graze P, Maher J, Ross HJ, Ellis PM, McNulty W, Kaplan E, Pautret V, Weber MR, Shepherd FA. Butts CA, et al. Among authors: ellis pm. J Clin Oncol. 2007 Dec 20;25(36):5777-84. doi: 10.1200/JCO.2007.13.0856. J Clin Oncol. 2007. PMID: 18089875 Clinical Trial.
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Goodwin R, Ding K, Seymour L, LeMaître A, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, Walde D, Laberge F, Vincent M, Ellis PM, Laurie SA; from the NCIC Clinical Trials Group, Kingston, Ontario, Canada. Goodwin R, et al. Among authors: ellis pm. Ann Oncol. 2010 Nov;21(11):2220-2226. doi: 10.1093/annonc/mdq221. Epub 2010 Apr 28. Ann Oncol. 2010. PMID: 20427348 Free article. Clinical Trial.
221 results